Wednesday, June 10, 2026

Patent intelligence Β· HR

HR P20190642

ARIPIPRAZOLE PRODRUG COMPOSITIONS

granted A61K 9/ 00 A IA61K 9/ 14 A IA61K 31/ 4704 A IA61K/3100
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 25
Patent details β€” HR P20190642
Jurisdiction
HR
Status
granted
Grant date
May 31, 2019
Expiration
May 26, 2039
CPC classes
A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100
View on Google Patents β†—

Quick answer

HR P20190642 (ARIPIPRAZOLE PRODRUG COMPOSITIONS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 31, 2019. Expires May 26, 2039 (13 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
β€”
CPC classes
A61K 9/ 00 A I, A61K 9/ 14 A I, A61K 31/ 4704 A I, A61K/3100, A61K/90019, A61K/9145

More from ALKERMES PHARMA IRELAND LTD [IE]

Related pharmaceutical patents in our USPTO index.

  1. AU 2022263543

    Pharmaceutical compositions comprising sorbitan esters

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires May 18, 2044

    granted
  2. US 2023302008

    METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Sep 23, 2043

    granted
  3. WO 2023156493

    FORMES CRISTALLINES DE NALTREXONE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Aug 19, 2043

    granted
  4. WO 2023154894

    COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Aug 12, 2043

    granted
  5. CY 2022006

    Ξ Ξ‘ΞŸΞ¦Ξ‘Ξ‘ΞœΞ‘ΞšΞ‘ ΦΟΞ₯ΞœΞ‘Ξ‘Ξ™ΞšΞ©Ξ ΑΛΑ΀ΩΝ ΞšΞ‘Ξ™ Ξ— ΧΑΗΣΗ ΀ΟΞ₯Ξ£ Σ΀ΗΝ ΑΓΩΓΗ Ξ ΞŸΞ™ΞšΞ™Ξ›Ξ©Ξ ΝΟΣΩΝ

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Dec 31, 2042

    granted
  6. US 2022354866

    IMMEDIATE RELEASE MULTILAYER TABLET

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 5, 2042

    granted
  7. CA 3172871

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 13, 2041

    granted
  8. CA 3172874

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] Β· Expires Nov 13, 2041

    granted

Frequently asked questions

What is US patent P20190642?

HR P20190642 (ARIPIPRAZOLE PRODRUG COMPOSITIONS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 31, 2019. Expires May 26, 2039 (13 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns HR P20190642?

ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does HR P20190642 expire?

Our index shows an expiration date of May 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.